CS
AXSM icon

Candriam SCA’s Axsome Therapeutics AXSM Stock Holding History

Candriam SCA’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76,727
Closed -$8.01M – 667
2025
Q2 		$8.01M Sell
76,727
-3,203
-4% -$339K 0.05% 285
2025
Q1 		$9.32M Buy
+79,930
New +$9.11M 0.06% 246
2024
Q2 		– Sell
-75,084
Closed -$5.99M – 692
2024
Q1 		$5.99M Sell
75,084
-10,000
-12% -$839K 0.04% 313
2023
Q4 		$6.77M Buy
85,084
+35,000
+70% +$2.34M 0.05% 303
2023
Q3 		$3.5M Hold
50,084
– – 0.02% 355
2023
Q2 		$3.6M Sell
50,084
-45,000
-47% -$3.32M 0.03% 390
2023
Q1 		$5.4M Sell
95,084
-76,390
-45% -$5.02M 0.04% 346
2022
Q4 		$13.2M Buy
171,474
+61,094
+55% +$3.65M 0.09% 220
2022
Q3 		$4.92M Sell
110,380
-4,704
-4% -$235K 0.03% 381
2022
Q2 		$4.41M Hold
115,084
– – 0.04% 342
2022
Q1 		$4.76M Buy
115,084
+20,727
+22% +$643K 0.03% 359
2021
Q4 		$3.56M Sell
94,357
-59,245
-39% -$2.18M 0.02% 430
2021
Q3 		$5.06M Buy
153,602
+35,000
+30% +$1.36M 0.03% 398
2021
Q2 		$8M Buy
118,602
+2,800
+2% +$168K 0.05% 318
2021
Q1 		$9.06M Hold
115,802
– – 0.08% 268
2020
Q4 		$9.44M Buy
115,802
+15,347
+15% +$1.15M 0.07% 274
2020
Q3 		$7.16M Buy
+100,455
New +$7.83M 0.07% 288

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Candriam SCA's AXSM Position: Q3 2025 in Review

Candriam SCA sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 76,727 shares — an estimated $8.01M sold.

Candriam SCA first reported a position in AXSM in Q3 2020 and held it in 17 quarters. The position peaked at $13.2M in Q4 2022. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Candriam SCA reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Candriam SCA sold 76,727 Axsome Therapeutics shares in Q3 2025, an estimated $8.01M.
  • Candriam SCA first reported a position in Axsome Therapeutics in Q3 2020 and held it in 17 quarters.
  • Candriam SCA's Axsome Therapeutics position peaked at $13.2M in Q4 2022.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Candriam SCA's 13F filing for Q3 2025, filed 6 Nov 2025.